Nippon Kayaku To Start Cancer Drug NK102’s U.S. Phase II Trial
This article was originally published in PharmAsia News
Executive Summary
Nippon Kayaku plans to start a Phase II trial for cancer drug NK102 in the U.S. this spring. The trial targets intractable breast cancer patients and the selection of the trial facility has entered the final stage. NK102 is developed on a new drug delivery system that encapsulates active metabolite of cancer drug camptothecin with polymer micelle. According to the company, the drug's Phase I trial started in January 2007 in the U.S. showed promising results. The company has set developing polymer micelle cancer drug as a priority, and currently stomach cancer drug NK105 (paclitaxel) and pancreatic drug NK911 (doxorubicin) are in Phase II trials in Japan. (Click here for more - Japanese language